Rivaroxaban Granule, For Suspension
Product Images NDC 67877-882

Product Visual Gallery

This gallery contains 33 technical images submitted to the FDA as part of the official labeling for Rivaroxaban (NDC 67877-882). Unlike standard consumer photos, these assets often include clinical data figures, molecular chemical structures, and official manufacturer packaging layouts.

As provided by Ascend Laboratories, Llc, these visuals offer a comprehensive scientific overview of the product's physical and chemical identity, aiding pharmacists and researchers in product verification and study.

FDA Label Image

Riv-cart-u-1 (Riv Cart U 1)

Rivaroxaban for Oral Suspension 1 mg/mL (when reconstituted) packaging label from Ascend Laboratories, LLC. The label includes dosing instructions, pharmacy use guidelines, storage conditions, contents (1 bottle, 2 oral dosing syringes, 1 plastic bottle adaptor, instructions for use), and caution statements. The suspension contains 155 mg of rivaroxaban per bottle and is for oral use only.*

FDA Label Image

Riv-fig-ifu1-u-b (Riv Fig Ifu1 U B)

An illustration of a purple oral syringe used for measuring and administering Rivaroxaban granule for suspension, labeled for the 155 mg/1 strength. The syringe has measurement markings in milliliters for accurate dosing.*

FDA Label Image

Riv-fig-ifu10-u (Riv Fig Ifu10 U)

A text panel advising not to shake the bottle too fast to avoid foaming, which may lead to administering the wrong dose.*

FDA Label Image

Riv-fig-ifu11-u (Riv Fig Ifu11 U)

An instructional diagram showing a close-up of a bottle with a focus on a checkmark symbol near the bottle's lower section, indicating a correct condition or step related to the bottle handling or inspection.*

FDA Label Image

Riv-fig-ifu12-u (Riv Fig Ifu12 U)

An instructional diagram labeled Step 3: Check the prescribed dose, likely part of a multi-step guide related to medication preparation or administration. The image emphasizes verifying the correct dose before proceeding.*

FDA Label Image

Riv-fig-ifu13-u (Riv Fig Ifu13 U)

A dosing instruction panel for rivaroxaban oral suspension advising to only use the oral dosing syringe provided with the product for accurate dosing.*

FDA Label Image

Riv-fig-ifu14-u-b (Riv Fig Ifu14 U B)

An illustration of an oral dosing syringe marked with volume graduations from 0.8 mL up to 3 mL, including intermediate markings such as 0.9, 1.1, 1.4, 1.6, 1.7, 1.8, 2, 2.4, 2.5, 2.8, and 3 mL. Different colored segments fill the inside of the syringe barrel, visually differentiating the measured volumes. The syringe capacity is indicated as 5 mL at the bottom.*

FDA Label Image

Riv-fig-ifu15-u (Riv Fig Ifu15 U)

A data table showing dose measurements correlating total volume in milliliters (mL) with combinations of 5 mL and smaller volumes (2.5 mL), illustrating dose preparation instructions by volume for oral suspension.*

FDA Label Image

Riv-fig-ifu16-u (Riv Fig Ifu16 U)

An instructional diagram titled 'Step 4: Set prescribed dose' illustrating the process of adjusting the dosage, likely related to Rivaroxaban granule for suspension oral medication. The image highlights dose setting as part of a multi-step administration guide.*

FDA Label Image

Riv-fig-ifu17-u-b (Riv Fig Ifu17 U B)

An instructional illustration showing a hand holding a bottle and inserting a syringe or dropper into it. A close-up circle highlights the bottle's opening area. A blue arrow points upward from the bottle's top, indicating a step in the process, likely related to extracting or preparing a suspension dose.*

FDA Label Image

Riv-fig-ifu18-u-b (Riv Fig Ifu18 U B)

An instructional illustration showing a hand holding a bottle with the cap removed and another hand inserting a bottle adapter into the bottle opening, indicating assembly for use with the oral granule suspension product.*

FDA Label Image

Riv-fig-ifu19-u-b (Riv Fig Ifu19 U B)

An instructional illustration showing a hand holding a syringe or similar dosing device with an arrow pointing downward, indicating a step in the preparation or administration process for oral suspension medication.*

FDA Label Image

Riv-fig-ifu2-u-b (Riv Fig Ifu2 U B)

An illustration of a purple oral dosing syringe marked with measurement graduations from 0.5 mL to 5 mL, used for administering liquid medication doses accurately.*

FDA Label Image

Riv-fig-ifu20-1u (Riv Fig Ifu20 1u)

A caution warning panel instructing to ensure enough medication for a full dose and not to take a partial dose. The text is presented in red with a warning icon.*

FDA Label Image

Riv-fig-ifu21-u-b (Riv Fig Ifu21 U B)

An instructional illustration showing a hand using a purple syringe to inject or draw liquid from an arm, with a magnified inset highlighting bubbles inside the syringe tip.*

FDA Label Image

Riv-fig-ifu22-u-b (Riv Fig Ifu22 U B)

An instructional illustration showing a person holding a vial upside down with one hand and using a syringe with the other hand to draw liquid from the vial. A blue arrow points upward indicating the direction of syringe movement.*

FDA Label Image

Riv-fig-ifu23-u-b (Riv Fig Ifu23 U B)

An illustration showing a person holding an oral suspension bottle with one hand while lifting a dosing device or syringe out of the bottle with the other hand, indicated by a blue upward arrow. It visually demonstrates the step of removing the dosing device from the liquid medication.*

FDA Label Image

Riv-fig-ifu24-u (Riv Fig Ifu24 U)

A text panel titled 'Step 5: Give the dose,' likely part of administration instructions for Rivaroxaban granules for oral suspension. The visible portion shows only the heading without further dosing details.*

FDA Label Image

Riv-fig-ifu25-u-b (Riv Fig Ifu25 U B)

Illustration showing the administration of oral granule medication to a child using an oral syringe placed near the child's mouth. The child's face is depicted with the hand holding the oral syringe, indicating oral dosing.*

FDA Label Image

Riv-fig-ifu26-u (Riv Fig Ifu26 U)

A text panel providing dosing instructions for Rivaroxaban granule for suspension. It advises that if the dose exceeds 5 mL, the same syringe must be used multiple times with repeated steps to complete the full dose.*

FDA Label Image

Riv-fig-ifu27-u (Riv Fig Ifu27 U)

An instructional panel titled 'Step 6: Rinse and store,' likely guiding the user through the final step of using a medication, emphasizing rinsing and properly storing the product.*

FDA Label Image

Riv-fig-ifu28-u-b (Riv Fig Ifu28 U B)

An instructional illustration showing two hands: one holding a syringe-like device and the other holding a purple cylindrical container. Blue dots represent water being poured from above into the syringe device, indicating a step in medication preparation or administration.*

FDA Label Image

Riv-fig-ifu29-u (Riv Fig Ifu29 U)

A warning panel instructing not to place the oral dosing syringe in the dishwasher, presented in red text on a white background.*

FDA Label Image

Riv-fig-ifu3-u-b (Riv Fig Ifu3 U B)

Illustration of an oral syringe with labeled parts: the tip at the top and the plunger at the bottom. The syringe features measurement markings along its length for precise dosing.*

FDA Label Image

Riv-fig-ifu4-u (Riv Fig Ifu4 U)

An illustration showing a brown glass bottle with a white cap and a bottle adaptor fitted on the neck. The diagram includes labeled parts: the cap on top and the bottle adaptor below with a caution note in red text stating 'Do not remove the bottle adaptor.' This image is likely related to the assembly or use of a medication bottle.*

FDA Label Image

Riv-fig-ifu5-u (Riv Fig Ifu5 U)

Instructional diagram titled 'Step 1: Get ready' illustrating preparation steps, likely part of a series of directions for use related to the medication, showing a hand and an object indicative of initial preparation actions.*

FDA Label Image

Riv-fig-ifu6-u (Riv Fig Ifu6 U)

An instructional illustration showing a bottle of Rivaroxaban granule for suspension with a note directing to check the "Discard after" date on the label. The focus is on locating the discard date information on the bottle's label for safe use.*

FDA Label Image

Riv-fig-ifu7-u (Riv Fig Ifu7 U)

An instructional illustration showing a pair of hands being washed or rinsed under a stream of water from a faucet. Blue dots represent water droplets in the flow onto the hands.*

FDA Label Image

Riv-fig-ifu8-u (Riv Fig Ifu8 U)

An instructional title panel labeled 'Step 2: Prepare rivaroxaban for oral suspension,' indicating a procedural step for preparing rivaroxaban granules for oral suspension.*

FDA Label Image

Riv-fig-ifu9-u (Riv Fig Ifu9 U)

An instructional illustration showing a hand holding a bottle, shaking it gently with the word 'SLOW!' in blue text above, indicating the need to shake the bottle slowly before use.*

FDA Label Image

Riv-fig2-u (Riv Fig2 U)

A pharmacokinetic (PK) fold change chart showing Cmax and AUC values with 90% confidence intervals for rivaroxaban in populations with varying renal impairment, age groups, body weight ranges, and hepatic impairment. The chart compares these PK parameters relative to reference groups, with specific notes on creatinine clearance levels for renal impairment.*

FDA Label Image

Riv-fig3-u (Riv Fig3 U)

A chart showing the fold change and 90% confidence interval for various interacting drugs on the pharmacokinetics (Cmax and AUC) of rivaroxaban. The drugs are categorized into Combined P-gp and Strong CYP3A Inhibitors, Combined P-gp and Moderate CYP3A Inhibitor, Moderate CYP3A Inhibitor, Combined P-gp and Strong CYP3A Inducer, and Other Drugs. The x-axis represents the change relative to rivaroxaban alone from 0.25 to 4 times.*

FDA Label Image

Riva-str-u (Riv Str U)

Chemical structure of the active ingredient rivaroxaban, showing the arrangement of atoms and bonds in its molecular framework.*

* About these descriptions: Image descriptions on this page are generated by automated AI analysis of the product label images from the manufacturer's FDA label submission (SPL). They are provided for reference only and may contain errors or omissions. Always rely on the printed label itself and the official FDA labeling, and consult a pharmacist or healthcare professional with any questions about this product.